Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville

Solange Flore Mongo Ngamami; Ruddy Junior Taty; Kivie Mou-moue Ngolo Letomo; Christian Michel Kouala Landa; Gankama Thibault Naibe; Jospin Karel Makani Bassoukouahou; Rog Paterne Bakekolo; Meo Stephane Ikama; Fikahem Ellenga Mbolla

doi:doi:10.11648/j.ccr.20240801.11

Research Article |

Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville

Solange Flore Mongo Ngamami, Ruddy Junior Taty, Kivie Mou-moue Ngolo Letomo^*, Christian Michel Kouala Landa, Gankama Thibault Naibe, Jospin Karel Makani Bassoukouahou, Rog Paterne Bakekolo, Meo Stephane Ikama, Fikahem Ellenga Mbolla

Published in Cardiology and Cardiovascular Research (Volume 8, Issue 1)

Received: 15 December 2023 Accepted: 27 December 2023 Published: 18 January 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1^st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.

Published in	Cardiology and Cardiovascular Research (Volume 8, Issue 1)
DOI	10.11648/j.ccr.20240801.11
Page(s)	1-6
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

PAH, Left Heart Disease, Brazzaville, Congo

References

[1]	Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 11 oct 2022; 43(38): 3618 731.
[2]	Collège national des enseignants de cardiologie et de la société française. Cardiologie. 2^E édition ELSEVIER MASSON, Paris 2015; 284 P.
[3]	Thienemann F, Dzudie A, Mocumbi AO, et al. Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. BMJ Open. 2014; 4(10): e005950.
[4]	Galiè N, Humbert M, Vachiery JL, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1): 67-119, 2016.
[5]	Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022; 2200879.
[6]	Jingi AM, Noubiap JJ et al. Prevalence and determinants of pulmonary hypertension in a group of Cameroonian patients without chronic lung disease: a cross-sectional echocardiographic study. BMC Res Notes 2017; 10: 571.
[7]	Koné A, Koffi MOB, Samaké K, Djegbeton A, Kouraogo BW, Mobio LNA, et al. Difficulties in the management of pulmonary hypertension in a pneumology department in Abidjan, Côte d'Ivoire. Revue des Maladies Respiratoires Actualités. 2023; 15(1): 211 2.
[8]	Balola MB, Mateso GQM, Munyerenkana RB, Nzabara F, Maheshe G. Causes of pulmonary hypertension in South Kivu, case of Bukavu Provincial General Reference Hospital. Ann afr méd (Online). 2020; 3829 39.
[9]	Ovaga BE. Exclusive right heart failure in the Department of Cardiology and Internal Medicine at Brazzaville University Hospital. Thèse de Médecine. Université Marien Ngouabi; 2016, 74P. v.
[10]	Simonneau G, Moutari D et al. Haemodynamic definitions and updated Clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.
[11]	Rochon ER, Krowka MJ, Bartolome S, et al: BMP 9/10 in pulmonary vascular complications of liver disease. Am J Respir Crit Care Med 201(11): 1575–1578, 2020. doi: 10.1164/rccm.201912-2514LE.
[12]	Beghetti M, Simonneau G. Classification de l’hypertension artérielle pulmonaire. Arch Cardiol Desease 2010; 2: 132-136.
[13]	Reinero C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, et al. ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med. mars 2020; 34(2): 549 73.
[14]	Choudhary G, Jankowich M. Prevalence and Clinical Characteristics Associated with Pulmonary Hypertension in African-Americans. PloS One. 2013. 8(12): e84264.
[15]	Enea I, Ghio S et al. Echocardiographic alterations suggestive of pulmonary hypertension in the italian ultrasonography laboratories. Epidemiological data from the INCIPT study. G Ital Cardiol. Rome. 2010. 11: 402-407.
[16]	Sobanski V, Sanges S, Launay D, Humbert M. Hypertension pulmonaire et connectivites. Revue du rhumatisme monographies. 2018; 85(3): 210 20.
[17]	Badesch DB, Raskob GE. Pulmonary arterial hypertension: Baseline charactéristics from the REVEAL registry. Chest 2010: 137(2): 376-387.
[18]	Dzudie A et al. Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. Cardiovasc J Afr 2018; 29(4): 208-212.
[19]	Ngunga M et al. Long-Term Outcomes and Factors Associated with Mortality in Patients with Moderate to Severe Pulmonary Hypertension in Kenya. Global Heart. 2020; 15(1); 6.
[20]	Vachiéry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. janv 2019; 53(1): 1801897.
[21]	Ikama SM et al. Epidemiological and clinical profile of dilated cardiomyopathy at the Centre Hospitalier Universitaire de Brazzaville, Congo. Pan African Medical Journal. 2018; 31: 164.
[22]	Cassady SJ, Ramani GV. Right Heart Failure in Pulmonary Hypertension. Cardiol Clin. mai 2020; 38(2): 243 55.
[23]	Cappola et al. Pulmonary hypertension and myocarditis: a higher risk of death. Circulation 2002. (https://www.caducee.net/actualité-medicale/3554/hypertension-pulmonaire-et-myocardite.html).
[24]	Maloir Q, PETITJEAN H, Parzibut G, Weber T, DAVIDSEN C, Dulgheru E, et al. New developments in the diagnosis and risk stratification of pulmonary hypertension. Revue Médicale de Liège [Internet]. 2023 [cited 19 Nov 2023]; 78(2). Available from: https://orbi.uliege.be/handle/2268/300917

Cite This Article

Plain Text BibTeX RIS

APA Style

Ngamami, S. F. M., Taty, R. J., Letomo, K. M. N., Landa, C. M. K., Naibe, G. T., et al. (2024). Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiology and Cardiovascular Research, 8(1), 1-6. https://doi.org/10.11648/j.ccr.20240801.11

Copy | Download

ACS Style

Ngamami, S. F. M.; Taty, R. J.; Letomo, K. M. N.; Landa, C. M. K.; Naibe, G. T., et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol. Cardiovasc. Res. 2024, 8(1), 1-6. doi: 10.11648/j.ccr.20240801.11

Copy | Download

AMA Style

Ngamami SFM, Taty RJ, Letomo KMN, Landa CMK, Naibe GT, et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol Cardiovasc Res. 2024;8(1):1-6. doi: 10.11648/j.ccr.20240801.11

Copy | Download

@article{10.11648/j.ccr.20240801.11,
  author = {Solange Flore Mongo Ngamami and Ruddy Junior Taty and Kivie Mou-moue Ngolo Letomo and Christian Michel Kouala Landa and Gankama Thibault Naibe and Jospin Karel Makani Bassoukouahou and Rog Paterne Bakekolo and Meo Stephane Ikama and Fikahem Ellenga Mbolla},
  title = {Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville},
  journal = {Cardiology and Cardiovascular Research},
  volume = {8},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.ccr.20240801.11},
  url = {https://doi.org/10.11648/j.ccr.20240801.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ccr.20240801.11},
  abstract = {Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville
AU  - Solange Flore Mongo Ngamami
AU  - Ruddy Junior Taty
AU  - Kivie Mou-moue Ngolo Letomo
AU  - Christian Michel Kouala Landa
AU  - Gankama Thibault Naibe
AU  - Jospin Karel Makani Bassoukouahou
AU  - Rog Paterne Bakekolo
AU  - Meo Stephane Ikama
AU  - Fikahem Ellenga Mbolla
Y1  - 2024/01/18
PY  - 2024
N1  - https://doi.org/10.11648/j.ccr.20240801.11
DO  - 10.11648/j.ccr.20240801.11
T2  - Cardiology and Cardiovascular Research
JF  - Cardiology and Cardiovascular Research
JO  - Cardiology and Cardiovascular Research
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2578-8914
UR  - https://doi.org/10.11648/j.ccr.20240801.11
AB  - Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.

VL  - 8
IS  - 1
ER  -

Copy | Download

Author Information

Solange Flore Mongo Ngamami

Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo

Contact Email
Ruddy Junior Taty

Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo
Kivie Mou-moue Ngolo Letomo

Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo

Contact Email
Christian Michel Kouala Landa

Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo
Gankama Thibault Naibe

Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo
Jospin Karel Makani Bassoukouahou

Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo
Rog Paterne Bakekolo

Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo
Meo Stephane Ikama

Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo
Fikahem Ellenga Mbolla

Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo

Contact Email

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Ngamami, S. F. M., Taty, R. J., Letomo, K. M. N., Landa, C. M. K., Naibe, G. T., et al. (2024). Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiology and Cardiovascular Research, 8(1), 1-6. https://doi.org/10.11648/j.ccr.20240801.11

Copy | Download

ACS Style

Ngamami, S. F. M.; Taty, R. J.; Letomo, K. M. N.; Landa, C. M. K.; Naibe, G. T., et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol. Cardiovasc. Res. 2024, 8(1), 1-6. doi: 10.11648/j.ccr.20240801.11

Copy | Download

AMA Style

Ngamami SFM, Taty RJ, Letomo KMN, Landa CMK, Naibe GT, et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol Cardiovasc Res. 2024;8(1):1-6. doi: 10.11648/j.ccr.20240801.11

Copy | Download

@article{10.11648/j.ccr.20240801.11,
  author = {Solange Flore Mongo Ngamami and Ruddy Junior Taty and Kivie Mou-moue Ngolo Letomo and Christian Michel Kouala Landa and Gankama Thibault Naibe and Jospin Karel Makani Bassoukouahou and Rog Paterne Bakekolo and Meo Stephane Ikama and Fikahem Ellenga Mbolla},
  title = {Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville},
  journal = {Cardiology and Cardiovascular Research},
  volume = {8},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.ccr.20240801.11},
  url = {https://doi.org/10.11648/j.ccr.20240801.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ccr.20240801.11},
  abstract = {Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville
AU  - Solange Flore Mongo Ngamami
AU  - Ruddy Junior Taty
AU  - Kivie Mou-moue Ngolo Letomo
AU  - Christian Michel Kouala Landa
AU  - Gankama Thibault Naibe
AU  - Jospin Karel Makani Bassoukouahou
AU  - Rog Paterne Bakekolo
AU  - Meo Stephane Ikama
AU  - Fikahem Ellenga Mbolla
Y1  - 2024/01/18
PY  - 2024
N1  - https://doi.org/10.11648/j.ccr.20240801.11
DO  - 10.11648/j.ccr.20240801.11
T2  - Cardiology and Cardiovascular Research
JF  - Cardiology and Cardiovascular Research
JO  - Cardiology and Cardiovascular Research
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2578-8914
UR  - https://doi.org/10.11648/j.ccr.20240801.11
AB  - Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.

VL  - 8
IS  - 1
ER  -

Copy | Download